IDYA IDEAYA Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IDYA

Price (delayed)

$29.285

Market cap

$2.57B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.58

Enterprise value

$2.44B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 46

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates ...

Highlights
The revenue is up by 3% since the previous quarter
The company's gross profit rose by 3% QoQ
The EPS has surged by 57% year-on-year but it has declined by 23% since the previous quarter
The net income has soared by 54% YoY but it has contracted by 23% from the previous quarter
The quick ratio has decreased by 24% YoY and by 4.8% from the previous quarter
The company's debt rose by 10% YoY and by 2.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ideayabio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IDYA

IDYA stock price

How has the IDEAYA Biosciences stock price performed over time
Intraday
3.12%
1 week
-0.19%
1 month
1.33%
1 year
38.79%
YTD
-15.29%
QTD
-12.11%

Financial performance

How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$225.27M
Gross profit
$225.27M
Operating income
-$183.47M
Net income
-$140.06M
Gross margin
100%
Net margin
-62.2%
The company's net margin has surged by 99% YoY but it fell by 20% QoQ
IDEAYA Biosciences's operating margin has soared by 98% YoY but it has decreased by 12% from the previous quarter
The net income has soared by 54% YoY but it has contracted by 23% from the previous quarter
IDYA's operating income is up by 49% year-on-year but it is down by 15% since the previous quarter

Price vs fundamentals

How does IDYA's price correlate with its fundamentals

Growth

What is IDEAYA Biosciences's growth rate over time

Valuation

What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
2.74
P/S
11.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.84
The EPS has surged by 57% year-on-year but it has declined by 23% since the previous quarter
IDEAYA Biosciences's equity has decreased by 8% YoY and by 8% QoQ
The stock's P/B is 6% above its 5-year quarterly average of 2.5 and 6% above its last 4 quarters average of 2.5
The stock's price to sales (P/S) is 90% less than its 5-year quarterly average of 114.1 and 85% less than its last 4 quarters average of 76.0
The revenue is up by 3% since the previous quarter

Efficiency

How efficient is IDEAYA Biosciences business performance
The return on sales has surged by 99% year-on-year but it has declined by 20% since the previous quarter
IDYA's ROIC has soared by 55% YoY but it is down by 27% from the previous quarter
The ROA has soared by 54% YoY but it has contracted by 24% from the previous quarter
The company's return on equity has surged by 52% YoY but it fell by 26% QoQ

Dividends

What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDYA.

Financial health

How did IDEAYA Biosciences financials performed over time
The quick ratio has decreased by 24% YoY and by 4.8% from the previous quarter
IDYA's current ratio is down by 23% YoY and by 5% QoQ
The company's debt is 97% lower than its equity
The company's debt rose by 10% YoY and by 2.5% QoQ
IDEAYA Biosciences's equity has decreased by 8% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.